Kalaris Therapeutics to Present at the Stifel Healthcare Conference
Kalaris Therapeutics, Inc. (NASDAQ: KLRS), a pioneering clinical-stage biopharmaceutical company focusing on treatments for retinal diseases, has announced its participation in a prestigious healthcare conference. This event is an excellent opportunity for the company to engage with investors and industry stakeholders while highlighting its innovative strategies and research efforts.
Details of the Presentation
Presentation Overview
The management of Kalaris will present key insights regarding their ongoing initiatives and future goals during the conference. Andrew Oxtoby, Chief Executive Officer, and Matthew Feinsod, Chief Medical Officer, will lead the discussion. Their expertise promises to provide valuable information on the company's approach to tackling prevalent retinal diseases.
Event Information
The presentation is set for November 13, 2025, from 3:20 PM to 3:50 PM ET. While the specific location is the Lotte New York Palace Hotel, it demonstrates Kalaris's commitment to being at the forefront of the biopharmaceutical landscape.
Opportunity for One-on-One Meetings
During the conference, Kalaris management will also be available for individual meetings. Interested parties are encouraged to reach out through their conference representative to arrange these discussions. This approach allows for more personalized engagement, answering queries related to their advanced therapeutic developments.
About Kalaris Therapeutics
Kalaris Therapeutics is dedicated to the advancement of treatments for significant retinal diseases that have urgent medical needs. Founded by Dr. Napoleone Ferrara, a leader in the field of anti-VEGF therapy, the company is committed to providing innovative solutions for patients affected by serious conditions such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
New Developments on the Horizon
In recent years, Kalaris has intensively pursued the development of novel therapies, enhancing its pipeline and showcasing promising results in clinical trials. The company’s ongoing research aims not only to address current gaps in treatment but also to improve patients’ quality of life through innovative therapeutic methods.
Contact Information for Investors
For inquiries regarding Kalaris's initiatives or investor relations, Corey Davis, Ph.D. of LifeSci Advisors, is the primary contact. He can be reached at +1 212 915 2577 or through email for any detailed discussions about the company’s strategies and financial positions.
Frequently Asked Questions
What is Kalaris Therapeutics focused on?
Kalaris Therapeutics focuses on developing treatments for prevalent retinal diseases with significant unmet medical needs.
Who will be presenting at the Stifel conference?
Andrew Oxtoby, CEO, and Matthew Feinsod, CMO, will present during the conference.
When is Kalaris's presentation scheduled?
Kalaris's presentation is scheduled for November 13, 2025, from 3:20 PM to 3:50 PM ET.
How can investors meet with Kalaris management?
Investors can arrange one-on-one meetings during the conference by contacting their conference representative.
What innovative work is Kalaris doing?
Kalaris is working on novel therapies to treat retinal conditions such as nAMD, DME, and RVO, aiming to improve patient outcomes and quality of life.
